Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Low-dose rapamycin protects DNA in aging immune cells by reducing damage-induced cell death and senescence markers, suggesting mTOR inhibition preserves immune resilience through direct genoprotection rather than broad immunosuppression. This mechanistic clarity offers a more tractable regulatory and therapeutic pathway than the traditional anti-aging framing.
Niagen Bioscience secured a US patent protecting intravenous and injectable formulations of nicotinamide riboside (NR), a NAD+ precursor molecule that declines with age and cellular stress. The patent extends protection through 2044 and positions the company to dominate clinical delivery of NAD+ boosters, a market rapidly expanding across wellness clinics.
Fisetin, a plant-derived senolytic, reverses age-related endothelial dysfunction in aging mice by eliminating senescent endothelial cells and reducing the SASP factor CXCL12, which drives vascular dysfunction through oxidative stress and impaired nitric oxide production. This identifies a mechanistic pathway linking cellular senescence to cardiovascular aging and demonstrates functional recovery through targeted senolytic intervention.
A randomized, placebo-controlled trial in sedentary adults aged 65-85 found that weekly rapamycin (6 mg) blunted functional gains from a 13-week exercise program, with the placebo group showing greater improvements in chair-stand performance and related measures. The drug's 62-hour half-life likely prevented adequate recovery of mTORC1 signaling between training sessions, creating a pharmacokinetic conflict with exercise adaptation.
The FDA approved a higher-dose semaglutide formulation (Wegovy HD, 7.2 mg) in 54 days under expedited review, signaling that metabolic disease now carries national priority status alongside traditionally serious conditions. The approval demonstrates additional weight loss benefit with a comparable safety profile to lower doses, though gastrointestinal side effects remain common and new sensory symptoms warrant ongoing monitoring.
Aging amplifies the liver's inflammatory and metabolic response to high-fat diet, increasing hepatic steatosis and transcriptional dysregulation. Rapamycin treatment reversed most diet-driven gene expression changes in older mice, reducing steatosis, body weight gain, and markers associated with liver disease progression.
Researchers demonstrated that combining NMN supplementation with apigenin—which inhibits NAD+ breakdown—restores muscle function and bone structure in aged mice. This dual approach addresses both supply and preservation of NAD+, a critical coenzyme in cellular energy metabolism and stress resistance.
A 16-week trial in 103 older adults (mean age 68) demonstrates that creatine supplementation amplifies the benefits of high-load, velocity-intentional resistance training—particularly in markers of neuroplasticity, oxidative stress, and inflammation—though cognitive gains showed no synergistic effect. This addresses a significant gap in gerontological research, as creatine has been understudied in aging populations where its ATP-enhancing properties could meaningfully support the preservation of fast-twitch muscle function.
Insilico Medicine's AI-designed drug ISM0676 achieved up to 31.3% weight loss in preclinical studies when combined with semaglutide, with a mechanistic approach targeting metabolic regulation rather than appetite suppression alone. The compound preserved lean muscle mass during weight loss and showed favorable safety and pharmacokinetic properties, suggesting potential advantages over current GLP-1 therapies for sustained metabolic health.
Dehydroepiandrosterone sulfate (DHEAS) levels correlate with subjective health perception in a longitudinal population study, suggesting this adrenal steroid may serve as a physiological marker for how individuals experience their own health status. The finding bridges objective biochemistry with subjective well-being, relevant to understanding which biomarkers meaningfully predict health experience across the lifespan.
NAD+ preservation through dual mechanisms—inhibiting its depletion and enhancing its synthesis—delays cellular senescence while promoting musculoskeletal regeneration. This addresses a central constraint in aging: the body's declining capacity to maintain energy production and tissue repair as NAD+ levels fall with time.
Researchers demonstrated that combining NAD+ precursor supplementation (NMN) with apigenin, a compound that reduces NAD+ degradation, restores muscle function and bone structure in aged mice. This dual-mechanism approach addresses both NAD+ availability and preservation, with relevance to human aging given prior clinical evidence for NAD+ precursors in metabolic and respiratory function.
Abinopharm released a white paper on AbinoNutra® NMN following FDA regulatory clarification confirming NMN's legality as a dietary supplement ingredient. A randomized, double-blind clinical trial demonstrated that 60 days of NMN supplementation at doses up to 900 mg increased blood NAD⁺ levels, improved physical performance and endurance, and showed favorable shifts in biological age markers with no serious adverse events.
Mitochondrial stress emerges as a critical mechanism underlying senolytic effectiveness against senescent cells. This finding suggests that the therapeutic benefit of senolytics depends partly on their capacity to induce cellular energy stress, offering a framework for optimizing drug selection and combination strategies in senescence-targeted interventions.
Eli Lilly's orforglipron demonstrated superior blood sugar control (2.2% reduction vs. 1.4%) and weight loss (9.2% vs. 5.3%) compared to oral semaglutide in the ACHIEVE-3 trial of 1,698 adults with type 2 diabetes. The oral formulation's flexibility—taken with meals rather than on an empty stomach—addresses a significant barrier to treatment adherence, though gastrointestinal side effects occurred in approximately 60% of patients.
GLP-1 medications are associated with a 30% relative increase in osteoporosis risk and modest increases in gout and bone softening, likely driven by rapid weight loss reducing skeletal load and potential nutritional deficiencies. These findings do not negate the drugs' metabolic benefits but require integrated monitoring and support strategies during treatment.
Triple and dual agonist drugs like retatrutide and CagriSema target multiple metabolic pathways simultaneously, producing weight loss exceeding 20-30% in clinical trials. These medications represent a shift toward precision metabolic intervention, with implications for both obesity management and aging-related cellular stress.
A combination of NMN and apigenin preserves NAD+ levels, activating SIRT3 to suppress cellular senescence and promote differentiation of muscle, bone, and cartilage precursor cells. The regimen also modulates the gut microbiota to increase production of phytosphingosine, an anti-aging metabolite, resulting in improved musculoskeletal function and exercise capacity in aged animals.
AT7687, a GIP receptor antagonist, targets fat storage pathways rather than appetite suppression, demonstrating tolerability and early metabolic improvements in human trials. Combined with cagrilintide in preclinical studies, the compound achieved weight loss exceeding either drug alone while preserving lean mass and improving insulin sensitivity without increased gastrointestinal burden.
Urolithin A activates mitophagy—the removal of damaged mitochondria—and prevents age-related cognitive decline when initiated early, but fails to reverse existing cognitive impairment when treatment begins after decline has already occurred. This temporal dependency defines a critical window for intervention in age-related neurodegeneration.
Antag Therapeutics is advancing AT7687, a GIP receptor antagonist peptide, showing tolerability and weight loss potential in early human trials and demonstrating synergistic metabolic benefits when combined with cagrilintide in preclinical work. The compound represents a mechanistic approach to obesity and insulin resistance through peptide-based receptor antagonism rather than agonism.
RevGenetics has developed DiBerberine 300x, an enteric-coated supplement combining dihydroberberine with a proprietary flavonoid complex designed to overcome two primary absorption barriers: stomach acid degradation and P-glycoprotein efflux. The formulation reportedly achieves 6.7-fold greater plasma exposure compared to standard berberine at lower doses, addressing a long-standing bioavailability limitation that has constrained berberine's clinical utility.
The European Medicines Agency recommended semaglutide for metabolic dysfunction-associated steatohepatitis (MASH), positioning it as the first GLP-1–based treatment for this silent liver disease in the EU. Approval would represent a significant shift from managing late-stage liver complications to intervening earlier in a metabolic disease that accelerates aging and reduces healthspan.
Two conjugated polyunsaturated fatty acids, α-eleostearic acid and its methyl ester, demonstrated senolytic activity in cell cultures and mouse models across multiple tissues without systemic toxicity. The structural features of these compounds—particularly conjugation patterns and double-bond configuration—correlate with their ability to eliminate senescent cells, which accumulate with age and drive inflammatory cascades linked to chronic disease.
